GlassScriptPhysician profile
Christy Watts
NPI 1215481221
$6,494.51
in general payments reported to CMS, 2019-2025
42 companies · $909 in 2025
The $909 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $931 · 2022: $1,157 · 2023: $2,008 · 2024: $1,490 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,406.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $801.27 | 2021-2025 | |
| Novo Nordisk INC | $754.97 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $669.72 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $503.93 | 2021-2025 | |
| Amgen INC. | $376.96 | 2021-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $323.89 | 2021-2025 | |
| Glaxosmithkline, LLC. | $290.53 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $246.12 | 2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.02 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $216.54 | 2021-2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $214.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $185.26 | 2024-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $163.98 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.48 | 2021-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $141.27 | 2021-2025 | Verquvo, Belsomra, Gardasil 9 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.